Incyte Biosciences Japan Gk
Clinical trials sponsored by Incyte Biosciences Japan Gk, explained in plain language.
-
New drug combo shows promise for tough-to-treat lymphoma in japanese patients
Disease control OngoingThis study tests the safety and effectiveness of tafasitamab alone or combined with other drugs (lenalidomide, parsaclisib, or R-CHOP) in about 72 Japanese adults with Non-Hodgkin lymphoma, including diffuse large B-cell lymphoma. The goal is to find the best doses and see if the…
Phase: PHASE1, PHASE2 • Sponsor: Incyte Biosciences Japan GK • Aim: Disease control
Last updated Jun 17, 2026 05:27 UTC
-
New hope for japanese patients with Hard-to-Treat chronic GVHD
Disease control OngoingThis study tests a drug called axatilimab in Japanese patients with chronic graft-versus-host disease (cGVHD) that has not improved after at least two prior treatments. cGVHD is a complication of stem cell transplants where donor cells attack the patient's body. The goal is to se…
Phase: PHASE3 • Sponsor: Incyte Biosciences Japan GK • Aim: Disease control
Last updated May 27, 2026 23:05 UTC